What are the recommended acute and preventive management strategies for short-lasting unilateral neuralgiform headache attacks (SUNA)?

SUNA Headache Management

Preventive Therapy (First-Line)

Lamotrigine is the most effective preventive treatment for SUNA, providing benefit in approximately two-thirds of patients. 1, 2, 3, 4, 5

Lamotrigine Dosing Strategy

• Start at a low dose and titrate gradually to minimize side effects 2, 4
• Target therapeutic dose typically ranges from 100-400 mg/day, though optimal dosing must be individualized based on response and tolerability 3, 4
• Allow adequate trial duration (6-8 weeks at therapeutic dose) before declaring treatment failure 2

Second-Line Preventive Options

• Gabapentin may be more effective for SUNA than for SUNCT specifically, making it a strong alternative when lamotrigine fails or is not tolerated 3, 4
• Topiramate is considered a good secondary option with demonstrated efficacy in open-label series 1, 6, 4
• Oxcarbazepine can be used as an alternative anticonvulsant when lamotrigine and gabapentin are ineffective 1
• Carbamazepine has shown benefit in some patients, though evidence is less robust than for lamotrigine 3

Acute Management of Severe Exacerbations

Intravenous lidocaine is essential for managing acute exacerbations of intractable SUNA attacks during severe active phases. 1, 2, 6, 4

IV Lidocaine Protocol

• Administer as transitional therapy to decrease the flow of attacks during the worst periods 2, 3, 4
• This is the most efficacious acute intervention available, though individual attacks are too brief for abortive therapy 2, 3
• Subcutaneous lidocaine can also be used as an alternative route 6

Alternative Acute Interventions

• Intravenous corticosteroids have shown effectiveness for acute treatment of active phases 6
• No conventional abortive medications (triptans, NSAIDs) are effective due to the extremely brief duration of individual attacks (typically seconds to minutes) 3, 4

Interventional and Surgical Options for Refractory Cases

When medical therapy fails after adequate trials of lamotrigine, gabapentin, and other preventive agents, interventional approaches should be considered:

Neuromodulation (Highest Success Rates)

• Deep brain stimulation (DBS) of the ventral tegmental area/hypothalamus achieves successful response in 86.7% of patients (14/16) with mean follow-up of 25.3 months 2, 7
• Occipital nerve stimulation (ONS) provides successful response in 80.5% of patients (33/41) with mean follow-up of 42.5 months 7

Microvascular Decompression

• MVD of the trigeminal nerve is effective in 76.7% of patients (56/73) when neurovascular compression is documented on imaging 1, 2, 7
• Neurovascular compression is commonly observed in SUNA, making this a rational surgical target 1
• Mean follow-up after MVD is 42.4 months 7

Other Interventional Options

• Stereotactic radiosurgery (gamma knife) to the sphenopalatine ganglion and/or trigeminal nerve achieves 77.8% success rate (7/9 patients) with mean follow-up of 20.8 months 7
• Pulsed radiofrequency of the sphenopalatine ganglion provides 55.6% success rate (5/9 patients) with mean follow-up of 24.8 months 7
• Botulinum toxin injections around the symptomatic orbit can provide sustained relief in selective cases 1, 3
• Greater occipital nerve blockade has shown temporary/partial effectiveness 3

Critical Clinical Features to Recognize

Diagnostic Characteristics

• Attacks are strictly unilateral and side-locked with severe stabbing/neuralgiform pain lasting seconds to minutes 2, 8
• Prominent ipsilateral cranial autonomic symptoms are present, most commonly lacrimation, conjunctival injection, rhinorrhea, and nasal congestion 2, 8
• Cutaneous or intraoral trigger points are a striking feature—attacks can be provoked by light touch, chewing, or talking 1
• Pain predominantly affects the ophthalmic and/or maxillary distribution of the trigeminal nerve 8
• SUNA affects both sexes throughout the lifespan, not just older men as initially thought 1

Attack Frequency and Pattern

• Attacks are highly frequent (often dozens to hundreds per day), making preventive therapy the mainstay of management 1, 3
• Most cases present as episodic rather than chronic 8
• The relative frequency of SUNA among adults evaluated for headache or facial pain is approximately 0.32% 8

Common Pitfalls to Avoid

• Do not rely on abortive medications—individual attacks are too brief (seconds to minutes) for any acute medication to take effect 3, 4
• Do not abandon lamotrigine prematurely—allow adequate dose titration and trial duration (6-8 weeks at therapeutic dose) before switching 2, 4
• Do not overlook secondary causes—approximately 45-55% of SUNA patients remain refractory to medical therapy, and neuroimaging should be performed to exclude structural lesions or neurovascular compression 7
• Do not delay referral to a headache specialist or neurosurgeon when medical therapy fails—interventional options have high success rates (76-87%) in refractory cases 7

Treatment Algorithm

1. Initiate lamotrigine as first-line preventive therapy, titrating to therapeutic dose over 6-8 weeks 1, 2, 3, 4, 5
2. If lamotrigine fails or is not tolerated, switch to gabapentin (particularly effective for SUNA) 3, 4
3. If both fail, trial topiramate or oxcarbazepine as second-line agents 1, 6, 4
4. For acute severe exacerbations during active phases, use IV lidocaine as transitional therapy 1, 2, 6, 4
5. If medical therapy remains inadequate after trials of multiple preventive agents, obtain MRI/MRA to assess for neurovascular compression and refer for interventional options 1, 7
6. For medically refractory cases with documented neurovascular compression, microvascular decompression is the preferred surgical approach 1, 2, 7
7. For medically refractory cases without neurovascular compression, consider occipital nerve stimulation or deep brain stimulation based on availability and patient preference 2, 7